CMS Proposes National Coverage For Microvolt T-Wave Alternan Testing

Cambridge Heart (HeartWave II) appears to have prevailed in its quest to obtain national coverage for Microvolt T-Wave Alternan testing to evaluate patients at risk of sudden cardiac death, despite opposition from professional societies and the three major ICD firms